Meet Our Leadership Team
PathoQuest’s management team has significant experience and expertise in in vitro diagnostics, for the development, validation and commercialization of metagenomic solutions for the identification of pathogens.
Jean-Francois Brepson - President and CEO
Jean-François Brepson has over 20 years leadership experience in the Pharmaceutical Industry. Prior to joining PathoQuest, Mr. Brepson was a Senior Vice-President at IPSEN where he was responsible for leading the global GI-Oncology & Endocrinology Franchise. He made a decisive contribution to the creation of leading portfolio in Neuro-Endocrine Tumors in close collaboration with R&D and Business Development teams. He led the pre-launch of IPSEN first product in GI-Oncology on a worldwide basis. Prior to this, Mr. Brepson held several commercial operations positions at IPSEN including area Manager, BU Head, and General Manager in the EMEA region. Mr. Brepson has an Engineering Degree in Data Management System and a Master Degree in Foreign Trade. He has also earned “The Leadership & Innovation Certificate” for HEC in Paris and “The Blue Ocean Strategy Certificate” from INSEAD in Fontainebleau.
Pascale Beurdeley, Ph.D. - Chief Scientific Officer
Dr. Pascale Beurdeley has 18 years experience in the biotechnology industry. Prior to joining PathoQuest, Dr. Beurdeley held several positions at DiaxonHit (formerly ExonHit Therapeutics) with increasing responsibilities from Group Leader R&D to Executive Director R&D, Genomics where she contributed to the development and the promotion of the company’s proprietary platform for the analysis of gene expression and alternative splicing. Dr. Beurdeley was also in charge of the implementation and the management of innovative R&D projects for both internal and collaborative programs in oncology and Alzheimer’s disease. She also acquired significant expertise in the conception and development of innovative diagnostic products in compliance with regulatory requirements. Prior to joining ExonHit Therapeutics, Dr. Beurdeley held a researcher position in the translational medicine department at the Curie Institute. Dr. Beurdeley is graduated from the University Louis Pasteur (Strasbourg) and holds a Ph.D in Molecular and Cell Biology. She completed her training as a post-doctoral fellow at Magainin Pharmaceuticals Inc, focusing on her interest in antimicrobial peptides.
Oréda Boussadia, Ph.D., Executive MBA - Chief Marketing and Commercial Officer, Biologics Genomic Service
Stéphane Cruveiller, Ph.D. - Chief Technology Information Officer
Dr. Stéphane Cruveiller has 20 years of experience in the field of bioinformatics applied to genomics and is (co-)author of nearly 70 publications. Prior to joining PathoQuest, Dr. Cruveiller was Team Leader at the François Jacob Institute of Biology – Genoscope of the French Alternative Energies and Atomic Energy Commission (CEA) at the Laboratory of Bioinformatics Analyses for Genomics and Metabolism (LABGeM). He has conducted custom analytical developments to support the scientific community’s efforts to annotate newly sequenced microbial genomes. Dr. Cruveiller’s experience in Next-Generation Sequencing (NGS) data mining has led him to provide academic and industrial partners innovative services and tools for variant calling and differential gene expression analyses. Dr. Cruveiller has also recently managed national microbial metagenomics projects in France. Dr. Cruveiller graduated from University Paris VII and holds a Ph.D. in Genome Analysis and Molecular Modeling. He completed his post-doctoral training at the Stazione Zoologica Anton Dohrn in Naples, Italy where he contributed to important discoveries on the structure, organization and evolution of the vertebrate genome.
Christine Dangles - Human Resources and Facility Director
Violaine Mélen, PharmD, Quality Assurance and Regulatory Affairs Head
Violaine Mélen has over 12 years of experience in Regulatory Affairs, Risk Management, Quality Assurance and Clinical Affairs within the biotech and pharmaceutical industries. Most recently, Ms. Mélen was responsible for implementing risk management at Bio-Rad Laboratories, with a specific focus on infectious disease, to ensure compliance with regulations and standards for in-vitro diagnostic devices. As a part of her responsibilities, she developed an “overall risk management system approach” for Bio-Rad in-vitro diagnostic devices focusing on the interface between reagents, software, and hardware. Subsequent to the above, Ms. Mélen assumed additional responsibilities for vigilance-related activities at Bio-Rad, working closely with various health authorities. Prior to the above, Ms. Mélen worked for Air Liquide Healthcare where she was a Regulatory Affairs Specialist with responsibilities for the registration of medicinal gases in Europe and a Medico Marketing Specialist in Spain where she led post-marketing clinical studies for pain management. Previous to the above, Ms. Mélen was a Quality Control Manager at PANPHARMA where she managed the Control Laboratory for microbiological and analytical chemistry activities to ensure compliance with Good Manufacturing Practices (GMPs). Ms. Mélen has a Pharmacy degree from Paris Descartes University with Analytical Chemistry specialty and has also received Master’s Degrees in Quality Assurance Management for IV-DM and Biotechnology from the University of Angers.